WallStreetZenWallStreetZen

NYSE: RBOT
Vicarious Surgical Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for RBOT

Based on 1 analyst offering 12 month price targets for Vicarious Surgical Inc

Min Forecast
$8.50+5.07%
Avg Forecast
$8.50+5.07%
Max Forecast
$8.50+5.07%

Should I buy or sell RBOT stock?

Based on 1 analyst offering ratings for Vicarious Surgical Inc.

Hold
Strong Buy
0 analysts 0%
Buy
0 analysts 0%
Hold
1 analysts 100%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RBOT stock forecasts and price targets.

RBOT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-03-18

1 of 1

Forecast return on equity

Is RBOT forecast to generate an efficient return?

Company
-49.09%
Industry
22.93%
Market
67.12%
RBOT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RBOT forecast to generate an efficient return on assets?

Company
-30.39%
Industry
12.06%
RBOT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RBOT earnings per share forecast

What is RBOT's earnings per share in the next 3 years based on estimates from 2 analysts?

Avg 1 year Forecast
-$8.96
Avg 2 year Forecast
-$5.41
Avg 3 year Forecast
-$2.82

RBOT revenue forecast

What is RBOT's revenue in the next 1 years based on estimates from 1 analyst?

Avg 1 year Forecast
$15.0M

RBOT vs Medical Device Stocks

TickerPricePrice TargetUp/downsideConsensus
RBOT$8.09$8.50+5.07%Hold
ECOR$6.88$25.50+270.64%Strong Buy
VVOS$6.82$6.20-9.09%Buy
MODD$0.71N/AN/A
HYPR$0.77$1.06+37.84%Strong Buy
View Top Medical Device Stocks

Vicarious Surgical Stock Forecast FAQ

Is Vicarious Surgical Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSE: RBOT) stock is to Hold RBOT stock.

Out of 1 analyst, 0 (0%) are recommending RBOT as a Strong Buy, 0 (0%) are recommending RBOT as a Buy, 1 (100%) are recommending RBOT as a Hold, 0 (0%) are recommending RBOT as a Sell, and 0 (0%) are recommending RBOT as a Strong Sell.

If you're new to stock investing, here's how to buy Vicarious Surgical stock.

What is RBOT's earnings growth forecast for 2025-2027?

(NYSE: RBOT) Vicarious Surgical's forecast annual earnings growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast earnings growth rate of 20.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 20.14%.

Vicarious Surgical's earnings in 2025 is -$61,616,000.On average, 2 Wall Street analysts forecast RBOT's earnings for 2025 to be -$53,150,577, with the lowest RBOT earnings forecast at -$54,930,172, and the highest RBOT earnings forecast at -$51,370,981. On average, 2 Wall Street analysts forecast RBOT's earnings for 2026 to be -$32,092,033, with the lowest RBOT earnings forecast at -$42,057,767, and the highest RBOT earnings forecast at -$22,126,300.

In 2027, RBOT is forecast to generate -$16,728,195 in earnings, with the lowest earnings forecast at -$16,728,195 and the highest earnings forecast at -$16,728,195.

What is RBOT's revenue growth forecast for 2027-2027?

(NYSE: RBOT) Vicarious Surgical's forecast annual revenue growth rate of N/A is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 8.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.56%.

Vicarious Surgical's revenue in 2025 is $0.

In 2027, RBOT is forecast to generate $88,979,760 in revenue, with the lowest revenue forecast at $88,979,760 and the highest revenue forecast at $88,979,760.

What is RBOT's forecast return on assets (ROA) for 2025-2027?

(NYSE: RBOT) forecast ROA is -30.39%, which is lower than the forecast US Medical Devices industry average of 12.06%.

What is RBOT's Price Target?

According to 1 Wall Street analyst that have issued a 1 year RBOT price target, the average RBOT price target is $8.50, with the highest RBOT stock price forecast at $8.50 and the lowest RBOT stock price forecast at $8.50.

The Wall Street analyst predicted that Vicarious Surgical's share price could reach $8.50 by Mar 18, 2026. The average Vicarious Surgical stock price prediction forecasts a potential upside of 5.07% from the current RBOT share price of $8.09.

What is RBOT's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSE: RBOT) Vicarious Surgical's current Earnings Per Share (EPS) is -$10.44. On average, analysts forecast that RBOT's EPS will be -$8.96 for 2025, with the lowest EPS forecast at -$9.26, and the highest EPS forecast at -$8.66. On average, analysts forecast that RBOT's EPS will be -$5.41 for 2026, with the lowest EPS forecast at -$7.09, and the highest EPS forecast at -$3.73. In 2027, RBOT's EPS is forecast to hit -$2.82 (min: -$2.82, max: -$2.82).

What is RBOT's forecast return on equity (ROE) for 2025-2027?

(NYSE: RBOT) forecast ROE is -49.09%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.